Ocular Therapeutix, Inc. (OCUL) stock soared 15.59% in the current-market trading session at the price of $11.27 despite no fundamental reason. The last published news on the company’s website was the appointment of Karen-Leigh Edwards. OCUL is a leading biopharmaceutical company. It utilizes bioresorbable hydrogel-based technology to develop innovative therapies to treat eye diseases.
OCUL Appointed Karen-Leigh Edwards
On 28th September 2021, OCUL published that it had appointed Karen-Leigh Edwards as its Senior Vice President of Technical Operations. Dr. Edwards will be responsible for technical development, production, and supply chain operations. She has 20 years of experience in global enterprise-wide production operations and product lifecycle management strategies. Before joining OCUL, Dr. Edwards held multiple management positions at Alexion Pharmaceuticals. She has most recently served as the Head of External Manufacturing and Operations. She got an M.B.A. degree from MIT Sloan School of Management and did her Ph.D. from the University of Kansas.
Chief Executive Officer of OCUL, Antony Mattessich, remarked that they are delighted to welcome Karen-Leigh to the team. Her expertise across various disciplines at leading pharmaceutical companies will help the company develop supply chains and global manufacturing strategies.
Dr. Edwards remarked that this is an exciting time to join OCUL’s team. The company has recently launch DEXTENZA and has advanced towards the development of novel ophthalmic products. She looks forward to serving the technical operations team to build a world-class manufacturing organization to support the company’s growth, she added.
Merilee Raines Joined OCUL
Previously on 22nd September 2021, OCUL announced that Merilee Raines had joined its Board of Directors. The appointment became effective from 20th September 2021. Ms. Raines brought deep experience as she has 28 years of experience with IDEXX Laboratories, Inc. At IDEXX, she held several management positions and served as the Executive Vice President and Chief Financial Officer. Ms. Raines has also served as a member of the Board of Directors of Transmedics Group, Inc., Watts Water Technologies, Inc., and Excelitas Technologies Corporation. She got her M.B.A. degree from the University of Chicago and is a Certified Public Accountant.
Ms. Raines commented that OCUL had successfully leveraged its hydrogel platform to bring DEXTENZA to market. It has emerged as a highly developed ophthalmology company with differentiated products to drive long-term growth. She is pleased to be part of Ocular and its directing Board, she added.